Reply: Navigating the Role of Ticagrelor in Elective Complex PCI: Time to Rule Out or Reassess?

JACC Cardiovasc Interv. 2024 Apr 22;17(8):1070. doi: 10.1016/j.jcin.2024.03.018.
No abstract available

Publication types

  • Letter

MeSH terms

  • Clinical Decision-Making*
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / therapy
  • Hemorrhage / chemically induced
  • Humans
  • Patient Selection
  • Percutaneous Coronary Intervention* / adverse effects
  • Platelet Aggregation Inhibitors* / adverse effects
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Purinergic P2Y Receptor Antagonists / adverse effects
  • Purinergic P2Y Receptor Antagonists / therapeutic use
  • Risk Assessment
  • Risk Factors
  • Ticagrelor* / adverse effects
  • Ticagrelor* / therapeutic use
  • Treatment Outcome

Substances

  • Ticagrelor
  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists